The investment in Cellibre positions Symrise at the forefront of fermentation-derived ingredients.WHO: Founded in 2017, Cellibre is a cellular agriculture company that employs an organism-agnostic approach to turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Cellibre’s approach starts with the molecule first. They pick targets where biology will beat legacy means on price, quality, and supply resilience, and then select a cell chassis to engineer where nature has already done some of the heavy lifting. They have successfully de‑risked core elements of scale‑up with impressive capital discipline.WHY: With this investment, Symrise will leverage Cellibre’s world-class biotechnology platform to enable a more resilient supply chain, mitigating seasonal and cultivation variability.IN THEIR OWN WORDS: "This investment accelerates our biotechnology roadmap and strengthens our ability to deliver sustainable, high-quality solutions to our customers. Together with Cellibre, we will combine scientific expertise with application know-how and market reach to unlock new growth opportunities," said Imke Meyer, Project Lead for Biotechnology at Symrise."Since 2017, we have been led by the belief that biology is the future of manufacturing and we are committed to creating more resilient supply chains, delivering products that are lower cost and higher quality while limiting the impact on natural ecosystems," said Ben Chiarelli, CEO of Cellibre.